Press Release | ERDERA Clinical Trial Call

1:1
ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

ERDERA

Author

ERDERA

You might also be interested in

ERDERA trainings template (5)

Diagnostic Research Workstream – Session 2: Data Sharing, Data Management & Ethics

September 25 @ 1:00 pm - 2:00 pm
Intended for researchers, clinicians, data managers, ERN and National Mirror Group members involved in or interested in ERDERA diagnostic research.
How National Mirror Groups strengthen rare disease research and policy alignment in Europe

How National Mirror Groups strengthen rare disease research and policy alignment in Europe

By connecting national priorities with European initiatives, NMGs support stronger coordination, knowledge exchange and alignment across the rare disease ecosystem.
Scientist reading a journal article 2026

Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients

The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.
Conference "Advancement of Treatments for Rare Diseases" in Cyprus, June 2026

Cyprus conference connects European research priorities with the path to rare disease treatments

At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.

ERDERA's

search form